{"entity":{"id":"aren0532","kind":"trial","name":"COG AREN0532","aka":["AREN0532"],"tldr":"AREN0532 tested treating the lowest-risk Wilms tumours with surgery alone and no chemotherapy, and giving more treatment only to children whose tumours carried particular chromosome losses; both ideas worked and now guide how much therapy each child gets.","summary":"AREN0532 was the Children's Oncology Group's risk-stratified trial for favourable-histology Wilms tumour, enrolling 808 children. Those under two years with small stage I tumours (very low risk) had nephrectomy alone and were watched; the standard-risk groups received vincristine and dactinomycin, with doxorubicin and radiotherapy added by stage, and those whose tumours showed loss of heterozygosity at both 1p and 16q, a marker of relapse identified in NWTS-5, were moved to more intensive regimens.\n\nSurgery alone gave excellent survival in the very low-risk group, with the few relapses salvaged, and augmenting therapy for the 1p/16q loss group improved event-free survival compared with historical controls. The trial embedded molecular risk markers in Wilms tumour treatment for the first time.","status":"completed","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT00352534","url":"https://clinicaltrials.gov/study/NCT00352534"}],"tags":["subtype-trials"],"related":[],"cancers":["wilms-tumor","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":["vincristine","dactinomycin","doxorubicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00352534","phase":"3","setting":"Very low-risk and standard-risk favourable-histology Wilms tumour: nephrectomy alone with observation for very low-risk disease, and risk-adapted vincristine, dactinomycin and doxorubicin with or without radiotherapy for the rest, with treatment intensified for tumours with loss of heterozygosity at 1p and 16q","sponsor":"Children's Oncology Group","result":"Nephrectomy alone was adequate for very low-risk favourable-histology Wilms tumour, and intensified therapy improved outcomes for tumours with 1p and 16q loss of heterozygosity.","yearReported":2018,"enrolled":808,"outcomes":[]},"route":"/trials/aren0532/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"},{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/"}],"drug":[{"id":"dactinomycin","kind":"drug","name":"Dactinomycin (actinomycin D)","route":"/drugs/dactinomycin/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}]}}